SARS-CoV-2 recombinant protein vaccine monovalent B.1.351 Alternative Exploratory Formulation 2

This is a monovalent recombinant protein subunit vaccine candidate developed by Sanofi and GSK, specifically targeting the B.1.351 (Beta) variant of SARS-CoV-2. It utilizes Sanofi's baculovirus expression system to produce a prefusion-stabilized soluble spike (S) protein (preS dTM) and is formulated with GSK's AS03 adjuvant system. The Alternative Exploratory Formulation 2 refers to a specific experimental dosage (10 µg of antigen) tested during Phase 2 clinical trials (such as VAT00002) to optimize the immune response against emerging variants. The vaccine works by inducing neutralizing antibodies and T-cell responses against the viral spike protein, preventing viral entry into host cells.

Brand names

Vidprevtyn Beta

Other names

Sanofi-GSK Beta vaccineVAT00002 Formulation 2VAT-00002 Formulation 2VAT 00002 Formulation 2